Allergan, Gedeon Richter Unbowed By Cariprazine MDD Phase III Trial Failure
• By Alex Shimmings
Generate a summary of this article
Listen to this article
Allergan and Gedeon Richter have hit a buffer in the development of their antipsychotic cariprazine in the additional indication of major depressive disorder, but they plan to proceed with a further pivotal trial, and mollified analysts with the announcement of a filing timeline to bolster the drug's label in schizophrenia.
• Source: Shutterstock
Top-line Phase III data for Allergan PLC and Gedeon Richter Ltd.'s atypical antipsychotic Vraylar (cariprazine) show it failed to separate from placebo when used as an add-on therapy in patients with major depressive disorder (MDD) in a US study.
However, the companies are bloodied but unbowed by the blow, and plan to box on with another Phase III trial...
Keep up with the top pharma business news of the week. On the go.
GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.
As it posts third-quarter numbers that again reveal the decline of revenues from its multiple sclerosis portfolio, the US biotech major is entering into the hot area of targeted protein degradation to boost its immunology and neurology pipeline.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.